A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
ITV News Correspondent Lucy Watson is visiting North Korea and offers a glimpse of what ordinary life is like inside the secretive state.
The NHS has reportedly racked up a deficit of almost £1bn in the first three months of the financial year.
Jurgen Klopp has branded himself 'The Normal One' in his first press conference as the new Liverpool manager